The Official Journal of the Turkish Society Of Clinical Microbiology and Infectious Diseases (KLİMİK)

COVID-19

Filter Newest Oldest Showing 61-69 of 69 results
Original Article / VOLUME 5, ISSUE 4, DECEMBER 2023

Association of Serum Krebs von den Lungen-6 (KL-6) Levels and Disease Severity in Patients Hospitalized with COVID-19

Oğuz Evlice and others

Acute lung injury and sepsis are among the severe clinical outcomes of the coronavirus disease 2019 (COVID-19). Risk factors raise fatality rates, increase the burden on countries’ healthcare facilities, and significantly increase health expenditures due to prolonged inpatient periods. Several studies have revealed a severe illness course in COVID-19 patients, especially in males, older age, and comorbid (...) Read More

Brief Report / VOLUME 6, ISSUE 1, MARCH 2024

Comparison of the i-test COVID-19 Rapid Antigen Test with Real-Time Reverse Transcriptase PCR

Muhammet Çağrı Yıldız and others

Polymerase chain reaction (PCR) test is used in high-capacity laboratories in the diagnosis of COVID-19. On the other hand, rapid SARS-CoV-2 antigen tests require less technical expertise and laboratory capacity. Antigen tests, which are faster and cost-effective, are increasingly used in COVID-19 screening and diagnosis. This study aimed to compare the i-test (...) Read More

Original Article / VOLUME 6, ISSUE 1, MARCH 2024

Infection Risk Prediction in Healthcare Settings: Lessons from COVID-19 Contact Tracing

Salih Keskin and others

Contact tracing has been recognized as a critical process in controlling infectious disease epidemics. Its objectives include early identification of potentially infectious cases and prevention of the emergence of new clusters. In the context of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, in-hospital contact-tracing efforts (...) Read More

Original Article / VOLUME 6, ISSUE 1, MARCH 2024

Individualized High Dose Intravenous Anakinra Treatment in Cancer Patients with COVID-19 Associated Cytokine Storm: A Retrospective Controlled Study

Ramazan Çakmak and Murat Bektaş

Coronavirus disease 2019 (COVID-19) is a potentially life-threatening disease caused by SARS-CoV-2. Clinical findings of COVID-19 are ranged from asymptomatic to severe pneumoniae, acute respiratory distress syndrome, multiorgan failure and death. A severe COVID-19 course is associated with a higher inflammatory state (cytokine storm) due to the excessive release (...) Read More

Original Article / VOLUME 6, ISSUE 2, JUNE 2024

The COVID-19 Vaccine Hesitancy Among Healthcare Workers: An Exploration of Hesitancy Reasons and Suggestions to Improve Vaccination Rates

Bahar Madran and others

The global impact of the coronavirus disease (COVID-19) pandemic has been profound, affecting billions of lives worldwide. As of June 13, 2024, the virus has infected approximately 704 million people and led to a staggering death toll of 7 million. In the fight against this devastating virus, the development and distribution of COVID-19 vaccines have been identified (...) Read More

Original Article / VOLUME 6, ISSUE 2, JUNE 2024

COVID-19 Vaccines and COVID-19 in People Living with HIV

Muhammed Fatih Karaşın and others

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a strain of the coronavirus that causes COVID-19, spread rapidly around the world and was defined as a pandemic on March 12, 2020, by the World Health Organization. As of June 2023, more than 767 million cases were confirmed globally, along with 6.9 million deaths. Read More

Original Article / VOLUME 6, ISSUE 3, SEPTEMBER 2024

A New Biomarker Copeptin in Determining Disease Severity in COVID-19

Pınar Korkmaz and others

Coronavirus disease (COVID-19) remarkably impacted mortality rates and healthcare resources. The causative virus, SARS-CoV-2, is a member of the β family. Pulmonary manifestations of COVID-19 can range from asymptomatic infection to severe pneumonia and acute respiratory distress syndrome. Research regarding risk classifications [...] Read More

Original Article / VOLUME 6, ISSUE 3, SEPTEMBER 2024

The Efficacy of Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients and the Impact of the COVID-19 Pandemic: Multicenter Real-Life Data

Yunus Gürbüz and others

In 75-85% of cases of acute hepatitis C infection, the disease becomes chronic and carries a risk of developing liver failure and hepatocellular cancer. In its global hepatitis report published in 2017, the World Health Organization (WHO) reported that 71.1 (95% uncertainty interval [UI]: 62.1-79.0 million) million people were chronically infected with the hepatitis C virus [...] Read More